Repatha vs Altace
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| CA Repatha | CA Altace | |
|---|---|---|
| Generic name | evolocumab | ramipril |
| Drug class | PCSK9 Inhibitor (Biologic) | ACE Inhibitor |
| Treats | High cholesterol, cardiovascular disease | High blood pressure, heart protection |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Amgen | Sanofi |
| Year approved | 2015 | 1994 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $32M | $2M |
| Common side effects | Injection site reactions, Allergic reactions, Back pain, Fatigue | Dry cough, Dizziness, High potassium, Headache |
Frequently asked questions
Is Repatha or Altace better?
Neither is universally "better." Repatha (evolocumab) and Altace (ramipril) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Repatha and Altace?
Repatha is a PCSK9 Inhibitor (Biologic) made by Amgen, while Altace is a ACE Inhibitor made by Sanofi. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Repatha has the larger estimated TV advertising budget of the two.